Glaukos Corporation
GKOS
$161.66
+6.83%
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing products for glaucoma, corneal disorders, and retinal diseases. As a pioneer in micro-invasive glaucoma surgery (MIGS) with its iStent franchise and the recently launched iDose TR implant, the company holds a distinct competitive position in the ophthalmic device space. The current investor narrative centers on the commercial ramp of iDose TR, a first-of-its-kind long-duration intracameral implant that could transform glaucoma treatment, and the company's expanding pipeline in corneal health and retinal diseases. Recent attention has been driven by strong revenue growth and a series of bullish analyst reiterations, though the company remains unprofitable as it scales its new product launches.…
GKOS
Glaukos Corporation
$161.66
Investment Opinion: Should I buy GKOS Today?
Rating: Hold. Glaukos is a high-growth medtech company with accelerating revenue and improving margins, but the premium valuation and limited upside to analyst targets suggest the stock is fairly valued at current levels. The consensus rating is Strong Buy with an average target of $162.92, implying only 3.9% upside, which does not provide a sufficient margin of safety for new positions.
Supporting Evidence: Revenue grew 41.2% YoY to $150.6M in Q1 2026, accelerating from prior quarters. Gross margin is strong at 77.9%, and operating margin improved to -13.2%. The company has a low debt-to-equity ratio of 0.21 and a current ratio of 4.69. However, the trailing P/S of 12.7x is more than double the industry average, and the stock is near its 52-week high with a 1-month gain of 20.5%. Free cash flow remains negative at -$16.5M, though improving.
Risks & Conditions: The biggest risks are a deceleration in revenue growth below 30%, which could trigger multiple compression, and failure to achieve profitability as expected. This Hold would upgrade to Buy if the stock pulls back to $130 (near the June 2026 lows) or if revenue growth accelerates above 50% with positive free cash flow. It would downgrade to Sell if growth decelerates below 20% or if the company issues disappointing guidance. Overall, Glaukos appears fairly valued relative to its growth rate and peer multiples, but the risk/reward is balanced.
Sign up to view all
GKOS 12-Month Price Forecast
Glaukos has strong momentum with accelerating revenue growth and improving margins, but the stock's premium valuation and proximity to its 52-week high limit near-term upside. The base case of 35-40% growth and gradual margin improvement is most likely, with the stock trading around the average analyst target. The bull case requires iDose TR to exceed expectations, while the bear case hinges on competitive or reimbursement setbacks. Given the balanced risk/reward, a neutral stance is appropriate, with a potential upgrade if the stock pulls back to more attractive levels or if growth accelerates further.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Glaukos Corporation's 12-month outlook, with a consensus price target around $163.85 and implied upside of +1.4% versus the current price.
Average Target
$163.85
0 analysts
Implied Upside
+1.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$138 - $190
Analyst target range
Glaukos is covered by 12 analysts, with a consensus recommendation of Strong Buy (mean rating 1.23 on a 1-5 scale). The average price target is $162.92, implying approximately 3.9% upside from the current price of $156.84. The distribution shows no Sell ratings, with the majority at Buy or Overweight, indicating strong bullish sentiment. Recent ratings from Citigroup, Piper Sandler, Needham, BTIG, JP Morgan, and Wells Fargo have all been positive, with no downgrades in the past three months. The target price range spans from $138.00 (low) to $190.00 (high). The high target of $190 implies 21.1% upside and likely assumes successful iDose TR adoption and margin expansion, while the low target of $138 suggests a 12.0% downside, potentially pricing in competitive pressures or slower-than-expected growth. The spread between low and high is $52, or 33% of the average target, indicating moderate uncertainty. The tight consensus around Strong Buy and the recent string of bullish reiterations suggest analysts have high conviction in the growth story, though the modest upside to the average target implies that much of the optimism is already priced in.
Bulls vs Bears: GKOS Investment Factors
Glaukos presents a compelling growth story with accelerating revenue (41.2% YoY), strong gross margins (77.9%), and improving operating leverage, supported by a solid balance sheet and strong analyst conviction. However, the stock trades at a premium valuation (12.7x P/S vs. industry 4-6x), remains unprofitable with negative free cash flow, and is near its 52-week high with limited upside to the average analyst target. The bull case currently has stronger evidence given the accelerating growth trajectory and unique product portfolio, but the key tension is whether the company can sustain 40%+ revenue growth and achieve profitability before the premium valuation compresses. The single most important factor is the commercial adoption of iDose TR, which will determine if the current growth rate is sustainable or if the stock faces a de-rating.
Bullish
- Accelerating Revenue Growth: Q1 2026 revenue grew 41.2% YoY to $150.6M, accelerating from 35.6% in Q4 2025 and 27.9% in Q3 2025, driven by the iDose TR launch and strong Glaucoma segment sales of $58.4M.
- Strong Gross Margin Profile: Gross margin remained high at 77.9% in Q1 2026, consistent with recent quarters, indicating healthy product economics and pricing power for its proprietary MIGS and iDose TR implants.
- Improving Operating Leverage: Operating margin improved to -13.2% in Q1 2026 from -18.9% in Q4 2025, as revenue growth outpaced operating expense growth, signaling a clear path to profitability.
- Solid Balance Sheet with Low Debt: Debt-to-equity ratio is only 0.21 and current ratio is 4.69, with $108.1M cash providing ample runway for continued investment in growth and pipeline development.
Bearish
- Unprofitable with Negative Free Cash Flow: Q1 2026 net loss was -$19.8M (EPS -$0.34) and free cash flow was -$16.5M, though improving from -$133.7M net loss in Q4 2025 which included a large impairment charge.
- Elevated Valuation Multiples: Trailing P/S ratio of 12.7x is more than double the medical devices industry average of 4-6x, leaving little room for error if growth decelerates.
- Stock Near 52-Week High: Current price of $156.84 is at 99.4% of the 52-week high of $157.71, with a 1-month gain of 20.5%, suggesting potential overextension and risk of a pullback.
- Modest Upside to Analyst Target: Average analyst target of $162.92 implies only 3.9% upside from current levels, indicating that much of the positive sentiment is already priced in.
GKOS Technical Analysis
Glaukos is in a strong uptrend, with the stock up 59.6% over the past year and currently trading at $156.84, near the top of its 52-week range of $73.16 to $157.71—specifically at 99.4% of the high. This positioning near the upper bound suggests robust momentum and bullish sentiment, though it also raises the risk of overextension in the near term. The 1-year relative strength versus SPY is +38.7%, indicating significant outperformance. Over the past three months, the stock has gained 29.0%, and over the past month, it has surged 20.5%, accelerating sharply from the longer-term trend. This recent momentum is notably stronger than the 1-year pace, suggesting a potential breakout or catalyst-driven rally. However, the 1-month change of +20.5% far exceeds the 3-month change of +29.0%, implying that the acceleration is very recent and may be unsustainable without consolidation. The stock's beta of 0.754 indicates it is less volatile than the overall market, which is unusual for a high-growth medtech name but may reflect its niche positioning. Key support lies at the 52-week low of $73.16, while resistance is at the current all-time high of $157.71. A breakout above $157.71 would signal a continuation of the uptrend, potentially targeting the analyst high of $190. Conversely, a pullback below recent support near $130 (the June 2026 lows) could indicate a temporary correction. The low beta suggests that any downside may be less severe than the broader market, but the stock's high valuation multiples imply elevated risk if growth disappoints.
Beta
0.75
0.75x market volatility
Max Drawdown
-29.9%
Largest decline past year
52-Week Range
$73-$166
Price range past year
Annual Return
+72.4%
Cumulative gain past year
| Period | GKOS Return | S&P 500 |
|---|---|---|
| 1m | +13.7% | -1.6% |
| 3m | +12.5% | +1.5% |
| 6m | +35.4% | +5.4% |
| 1y | +72.4% | +14.8% |
| ytd | +46.0% | +7.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GKOS Fundamental Analysis
Glaukos delivered Q1 2026 revenue of $150.6 million, representing 41.2% year-over-year growth, accelerating from the 35.6% growth in Q4 2025 and 27.9% in Q3 2025. The revenue trajectory is clearly accelerating, driven by the iDose TR launch and strong Glaucoma segment sales of $58.4 million, while Corneal Health contributed $14.9 million. This growth rate is impressive for a medtech company and supports the bullish thesis, though the base is still relatively small. The company remains unprofitable, with Q1 2026 net income of -$19.8 million and EPS of -$0.34, but the net loss margin improved to -13.1% from -93.4% in Q4 2025, which included a large impairment charge. Gross margin is strong at 77.9%, consistent with recent quarters, indicating healthy product economics. Operating margin was -13.2%, improving from -18.9% in Q4 2025, as the company scales revenue faster than operating expenses. The path to profitability hinges on continued revenue growth and operating leverage, with analysts expecting positive EPS of $4.63 in the current fiscal year. Glaukos has a solid balance sheet with a current ratio of 4.69 and a low debt-to-equity ratio of 0.21, indicating minimal financial risk. However, free cash flow was negative at -$16.5 million in Q1 2026, though it turned positive in Q4 2025 at $3.9 million. The company has $108.1 million in cash, providing ample runway. ROE is deeply negative at -28.6%, reflecting the net losses, but this is expected to improve as profitability approaches. The negative free cash flow yield (-139.3x PCF) highlights that the company is still investing heavily in growth, but the low debt levels provide a cushion.
Quarterly Revenue
$150571000.0B
2026-03
Revenue YoY Growth
+41.2%
YoY Comparison
Gross Margin
77.9%
Latest Quarter
Free Cash Flow
$-18481000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GKOS Overvalued?
Since Glaukos has negative net income (TTM net loss), the P/E ratio is not meaningful. Therefore, we use the price-to-sales (P/S) ratio as the primary valuation metric. The trailing P/S ratio is 12.7x, which is elevated but common for high-growth medtech companies. The forward P/S is not directly provided, but based on estimated revenue of $1.55 billion, the forward P/S would be approximately 4.2x, implying the market expects significant revenue growth. Compared to the medical devices industry average P/S of roughly 4-6x, Glaukos trades at a premium of over 100% on a trailing basis, but the forward multiple is more in line with peers, reflecting the high growth expectations. The premium may be justified by the company's 41% revenue growth and unique product portfolio, but it leaves little room for error. Historically, Glaukos's P/S ratio has ranged from 28x to 52x over the past two years, so the current 12.7x is near the lower end of its historical range. This suggests that the stock may be relatively cheaper than its own history, potentially offering a value opportunity if growth continues. However, the historical P/S was inflated by lower revenue bases, so the compression is partly due to revenue growth outpacing stock price appreciation. The EV/Sales multiple of 16.4x further confirms the premium valuation, but the negative EV/EBITDA of -44.5x reflects the lack of profitability.
PE
-34.4x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-44.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Glaukos remains unprofitable with a Q1 2026 net loss of -$19.8M and negative free cash flow of -$16.5M, though the net loss margin improved to -13.1% from -93.4% in Q4 2025. The company has a low debt-to-equity ratio of 0.21 and $108.1M cash, providing a cushion, but continued cash burn could pressure the balance sheet if revenue growth slows. Revenue concentration in the Glaucoma segment (iStent franchise and iDose TR) exposes the company to product-specific risks, and the negative free cash flow yield (-139.3x PCF) highlights the need for sustained growth to justify the current valuation.
Market & Competitive Risks: The stock's trailing P/S of 12.7x is significantly above the medical devices industry average of 4-6x, making it vulnerable to valuation compression if growth disappoints. With a beta of 0.754, the stock is less volatile than the market, but any macro headwinds or sector rotation away from growth could still pressure the stock. The ophthalmic device market is competitive, with established players like Alcon and Johnson & Johnson, and new entrants could challenge iDose TR's market share. Recent news is sparse, but the lack of negative catalysts suggests the market is focused on execution.
Worst-Case Scenario: If iDose TR adoption stalls due to reimbursement issues or competitive launches, revenue growth could decelerate sharply, leading to analyst downgrades and multiple compression. In this scenario, the stock could fall to the 52-week low of $73.16, representing a -53.4% decline from the current price of $156.84. The analyst low target of $138 implies a -12.0% downside, but a more severe scenario could see the stock retest the $100 level, a -36.2% decline, based on historical volatility and the stock's max drawdown of -29.92% over the past year.
FAQ
The key risks include: (1) Commercial risk: iDose TR adoption may disappoint due to reimbursement issues or competition, causing revenue growth to decelerate. (2) Valuation risk: The trailing P/S of 12.7x leaves little room for error; a growth slowdown could trigger a de-rating. (3) Profitability risk: The company is still unprofitable with negative free cash flow (-$16.5M in Q1 2026), and any delay in achieving profitability could pressure the stock. (4) Macro risk: Although beta is low at 0.754, a recession could reduce elective procedure volumes, impacting sales. The most severe risk is a -53.4% decline to the 52-week low of $73.16 if the growth story unravels.
The 12-month outlook is balanced: the base case (50% probability) sees the stock trading between $150 and $170, with revenue growth of 35-40% and gradual margin improvement, aligning with the average analyst target of $162.92. The bull case (25% probability) targets $170-$190, driven by iDose TR outperformance and earlier profitability. The bear case (25% probability) sees the stock falling to $100-$138 if growth disappoints. The most likely scenario is the base case, with the stock consolidating near current levels as the market awaits further evidence of iDose TR adoption.
Glaukos's trailing P/S ratio of 12.7x is significantly above the medical devices industry average of 4-6x, suggesting it is overvalued relative to peers on a historical basis. However, the forward P/S based on estimated revenue of $1.55 billion is approximately 4.2x, which is more in line with the industry, reflecting the market's expectation of high growth. Historically, GKOS has traded at P/S multiples ranging from 28x to 52x over the past two years, so the current 12.7x is near the lower end of its own history, indicating it may be relatively cheaper than its past. Overall, the stock appears fairly valued given its growth rate, but any deceleration could lead to multiple compression.
Glaukos is a high-growth medtech company with accelerating revenue (41.2% YoY) and strong gross margins (77.9%), but it remains unprofitable with negative free cash flow. The stock trades at a premium valuation (12.7x P/S vs. industry 4-6x) and is near its 52-week high, with only 3.9% upside to the average analyst target of $162.92. For growth investors with a long-term horizon and tolerance for volatility, GKOS could be a good buy on pullbacks, especially if the stock corrects to the $130 level. However, for value-oriented or risk-averse investors, the current risk/reward is not compelling given the limited upside and high expectations priced in.
Glaukos is better suited for long-term investment given its growth stage, high revenue growth (41.2% YoY), and unprofitability. The stock's beta of 0.754 indicates lower volatility than the market, but its 1-month gain of 20.5% suggests short-term momentum that could reverse. With no dividend and negative free cash flow, the investment thesis relies on capital appreciation from successful product launches and margin expansion. A minimum holding period of 3-5 years is recommended to allow the iDose TR franchise to mature and the company to reach profitability. Short-term traders may find opportunities around earnings announcements, but the risk of sharp pullbacks is elevated near the 52-week high.